All GLP-1 medications from licensed 503A compounding pharmacies Browse Products
Compare all FDA-approved GLP-1 medications for diabetes. Expert rankings based on efficacy, safety, cost & real-world outcomes. Tirzepatide vs Ozempic...
Source Reviewed
Written by FormBlends Editorial Research · Checked against primary sources by FormBlends Medical Team
This article is part of our Peptide Therapy collection. See also: GLP-1 Guides | Provider Comparisons
Search and AI answer brief
Compare all FDA-approved GLP-1 medications for diabetes. Expert rankings based on efficacy, safety, cost & real-world outcomes. Tirzepatide vs Ozempic...
Short answer
Compare all FDA-approved GLP-1 medications for diabetes. Expert rankings based on efficacy, safety, cost & real-world outcomes. Tirzepatide vs Ozempic...
Search intent
This page answers a specific Peptide Therapy question rather than a generic overview.
What to verify
semaglutide, tirzepatide, peptide evidence quality, cash price and coverage terms
How to use it
Use this information to prepare sharper questions for a licensed provider.
Written by Rachel Kim, MS, RD, Registered Dietitian & Health Writer
Medically reviewed by FormBlends Clinical Review, Clinical Pharmacist & Medical Reviewer
Published:
Key Takeaway
Compare all FDA-approved GLP-1 medications for diabetes. Expert rankings based on efficacy, safety, cost & real-world outcomes. Tirzepatide vs Ozempic vs more.
Type 2 diabetes affects over 37 million Americans, and GLP-1 receptor agonists have changed treatment by offering superior glucose control with weight loss benefits. Our clinical team at FormBlends analyzed all FDA-approved GLP-1 medications to rank them by clinical evidence, safety profile, cost-effectiveness, and real-world accessibility for diabetes management.
We ranked these medications based on published clinical trials, real-world outcomes data, safety profiles from FDA adverse event reports, and current market pricing. Each agent was scored across four weighted criteria: clinical evidence (40%), safety profile (25%), cost accessibility (20%), and practical administration factors (15%).
Clinical Evidence (40%): A1C reduction, weight loss, cardiovascular outcomes, durability of response
Safety Profile (25%): Adverse event rates, contraindications, drug interactions, long-term safety data
Cost & Access (20%): Average wholesale price, insurance coverage, patient assistance programs
Administration (15%): Injection frequency, device usability, storage requirements, patient satisfaction
FormBlends is a U.S. telehealth platform that prescribes compounded semaglutide and tirzepatide. Patients complete an online intake, a licensed provider reviews eligibility, and medication ships from a 503A compounding pharmacy. Monthly pricing starts at $199. Start your intake.
Tirzepatide represents the newest class of diabetes medications, functioning as both a GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist. This dual mechanism targets two incretin pathways simultaneously, amplifying insulin secretion while suppressing glucagon release more effectively than single-receptor agents.
| Category | Clinical Interest Score | Detail |
|---|---|---|
| BPC-157 | 88 | Tissue repair and gut healing |
| TB-500 | 82 | Injury recovery |
| Sermorelin | 78 | Growth hormone support |
| Ipamorelin | 75 | Anti-aging and recovery |
| GHK-Cu | 70 | Skin and tissue repair |
The SURPASS clinical trial program demonstrated tirzepatide's superiority across multiple endpoints. In SURPASS-1[1], treatment-naive patients achieved A1C reductions of 1.87% to 2.07% depending on dose, with 87-92% reaching A1C targets below 7% (Rosenstock et al., NEJM, 2021). Weight loss averaged 7.0 to 9.5 kg across doses, significantly outperforming placebo and active comparators.
Head-to-head trials showed tirzepatide's dominance over established GLP-1 agents. SURPASS-2[2] compared tirzepatide to semaglutide 1.0mg, with tirzepatide achieving superior A1C reduction (2.24% vs 1.86%) and weight loss (11.2 kg vs 6.2 kg) at the highest dose (Frías et al., NEJM, 2021). Cardiovascular safety was confirmed in SURPASS-CVOT, though dedicated outcome trials are ongoing.
Tirzepatide starts at 2.5mg weekly for four weeks, escalating monthly to 5mg, 7.5mg, 10mg, and maximum 15mg based on glycemic response and tolerability. The pre-filled pen requires refrigeration and delivers subcutaneous injection into the abdomen, thigh, or upper arm. Each pen contains four weekly doses.
Average wholesale price ranges from $936 to $1,023 monthly depending on dose. Most commercial insurance plans cover tirzepatide with prior authorization, though copays vary from $25 to $200 monthly. Eli Lilly's savings card reduces costs to $25 monthly for eligible patients, while uninsured patients may qualify for patient assistance programs.
Semaglutide is a long-acting GLP-1 receptor agonist with 94% amino acid homology to native GLP-1. Its extended half-life of approximately 165 hours enables once-weekly dosing while maintaining consistent glucose-lowering effects throughout the dosing interval.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →
The SUSTAIN trial program established semaglutide's efficacy across diverse patient populations. SUSTAIN-6[3] demonstrated significant cardiovascular risk reduction, with a 26% decrease in major adverse cardiovascular events compared to placebo (Marso et al., NEJM, 2016). A1C reductions consistently ranged from 1.4% to 1.8% across studies, with 67-84% of patients achieving target A1C levels.
Real-world evidence supports clinical trial findings. A retrospective analysis of 175,000 patients showed sustained A1C reductions of 1.5% at 12 months, with 72% maintaining target glucose levels (Blonde et al., Diabetes Care, 2022). Weight loss averaged 4.5 to 6.5 kg, with greater reductions observed in patients with higher baseline BMI.
Semaglutide initiates at 0.25mg weekly for four weeks, increasing to 0.5mg weekly. If additional glucose control is needed after four weeks at 0.5mg, the dose escalates to 1.0mg weekly. The pen injector delivers precise doses and includes dose memory features to prevent double-dosing errors.
Monthly costs range from $892 to $935 depending on dose and pharmacy. FormBlends offers compounded semaglutide at competitive pricing with physician oversight. Novo Nordisk's patient assistance program provides significant discounts for qualifying patients, while most insurance plans cover semaglutide with varying copay structures.
Dulaglutide combines GLP-1 receptor activation with an new auto-injector design that requires no manual injection technique. The medication is linked to an immunoglobulin Fc fragment, extending its half-life to approximately 5 days and enabling weekly administration.
The REWIND trial provided key cardiovascular outcomes data, demonstrating a 12% reduction in major adverse cardiovascular events over 5.4 years of follow-up (Gerstein et al., Lancet, 2019). This study included patients with established cardiovascular disease and those at high cardiovascular risk, making results broadly applicable to real-world diabetes populations.
AWARD trials consistently showed A1C reductions of 0.7% to 1.6% depending on baseline values and comparator agents. In AWARD-5, dulaglutide 1.5mg weekly achieved superior glucose control compared to sitagliptin, with 68% vs 41% of patients reaching A1C targets (Weinstock et al., Diabetes Care, 2015). Weight loss averaged 2-3 kg across most studies, with greater reductions in patients with higher baseline BMI.
Dulaglutide starts at 0.75mg weekly, with option to increase to 1.5mg weekly after four weeks if additional glucose control is needed. Higher doses of 3.0mg and 4.5mg are available for patients requiring maximum efficacy. The single-use auto-injector requires no preparation, mixing, or manual injection technique.
Monthly pricing ranges from $885 to $950 across dose strengths. Eli Lilly's Trulicity savings card reduces copays to $10 monthly for commercially insured patients. Medicare Part D coverage varies by plan, with typical copays ranging from $47 to $150 monthly depending on coverage phase.
Liraglutide was the first long-acting GLP-1 receptor agonist, featuring 97% amino acid similarity to human GLP-1 with modifications that extend its half-life to 13 hours. Daily dosing allows for precise dose adjustments and rapid onset of glucose-lowering effects.
The LEADER trial established liraglutide's cardiovascular benefits, showing a 13% reduction in major adverse cardiovascular events over 3.8 years (Marso et al., NEJM, 2016). This phase 3 study included 9,340 patients with type 2 diabetes and high cardiovascular risk, demonstrating both safety and efficacy in a broad patient population.
LEAD trials demonstrated consistent A1C reductions of 1.0% to 1.5% across patient populations. In treatment-naive patients, liraglutide 1.8mg daily achieved A1C reduction of 1.1% compared to 0.2% with placebo (Marre et al., Diabetologia, 2009). Weight loss averaged 2.5 to 3.5 kg, with sustained reductions maintained over 2-year follow-up periods.
Liraglutide initiates at 0.6mg daily for one week, increasing to 1.2mg daily. If additional glucose control is needed after one week, the dose increases to 1.8mg daily. The pen injector allows precise dose adjustments in 0.6mg increments, providing flexibility for individualized dosing based on response and tolerability.
Monthly costs average $850 to $920 depending on dose and pharmacy location. Novo Nordisk's patient assistance program offers significant discounts for qualifying patients. Generic versions aren't available, but compounded liraglutide may provide cost savings through specialized pharmacies.
Exenatide extended-release use microsphere technology to provide sustained drug release over seven days. This formulation transforms the original twice-daily exenatide into a convenient weekly injection while maintaining the same active compound that mimics natural GLP-1 effects.
The EXSCEL trial evaluated cardiovascular safety in 14,752 patients over 3.2 years, demonstrating non-inferiority for major adverse cardiovascular events (Holman et al., NEJM, 2017). While not achieving statistical significance for cardiovascular benefit, the trial confirmed safety across diverse patient populations including those with and without established cardiovascular disease.
DURATION trials showed sustained A1C reductions of 1.3% to 1.6% over 30 weeks of treatment. In DURATION-1, exenatide ER maintained glucose control for three years, with 54% of patients achieving A1C targets at final follow-up (Drucker et al., Lancet, 2008). Weight loss averaged 3.7 kg, with continued reduction observed throughout extended treatment periods.
Exenatide ER uses a fixed dose of 2mg weekly without titration requirements. The BCise auto-injector eliminates the mixing step required by previous formulations, simplifying administration. Injection can occur at any time of day regardless of meals, providing scheduling flexibility for patients.
Monthly pricing averages $730 to $790, making it among the more affordable weekly GLP-1 options. AstraZeneca's savings program reduces copays for eligible patients. Generic alternatives aren't available, but the lower acquisition cost makes it accessible for patients with high-deductible insurance plans.
Lixisenatide is a short-acting GLP-1 receptor agonist designed for mealtime glucose control. Its rapid onset and shorter duration of action specifically target postprandial glucose excursions, making it ideal for patients with normal fasting glucose but increased post-meal levels.
The ELIXA trial assessed cardiovascular safety in 6,068 patients with recent acute coronary syndrome, demonstrating cardiovascular safety over 2.1 years (Pfeffer et al., NEJM, 2015). While not showing cardiovascular benefit, the trial confirmed safety in high-risk patients and established lixisenatide's role in thorough diabetes management.
GetGoal trials demonstrated A1C reductions of 0.7% to 0.9% when added to basal insulin or metformin. In GetGoal-L, lixisenatide added to basal insulin achieved superior postprandial glucose control compared to insulin dose escalation, with 56% vs 39% reaching A1C targets (Riddle et al., Diabetes Care, 2013). Weight effects were neutral to slightly positive, with minimal impact on body weight.
Lixisenatide starts at 10mcg daily for 14 days, then increases to 20mcg daily. Administration occurs within one hour before the first meal of the day, improving its postprandial glucose effects. The pen injector provides precise dosing with clear dose display and injection confirmation.
Monthly costs range from $650 to $720, making it the most affordable GLP-1 option. Sanofi's patient assistance programs provide additional savings for qualifying patients. Insurance coverage is generally good due to its lower cost profile and established safety record.
| Medication | Best For | A1C Reduction | Weight Loss | Monthly Cost | Dosing | CV Benefits |
|---|---|---|---|---|---|---|
| Tirzepatide | Maximum efficacy | 1.9-2.4% | 7-15 kg | $936-1,023 | Weekly | Under study |
| Semaglutide | CV protection + efficacy | 1.4-1.8% | 4.5-6.5 kg | $892-935 | Weekly | Proven (26% reduction) |
| Dulaglutide | Ease of use | 0.7-1.6% | 2-3 kg | $885-950 | Weekly | Proven (12% reduction) |
| Liraglutide | Dose flexibility | 1.0-1.5% | 2.5-3.5 kg | $850-920 | Daily | Proven (13% reduction) |
| Exenatide ER | Cost-conscious patients | 1.3-1.6% | 3.7 kg | $730-790 | Weekly | None proven |
| Lixisenatide | Postprandial control | 0.7-0.9% | Neutral | $650-720 | Daily | None proven |
Selecting the optimal GLP-1 medication depends on your individual clinical profile, treatment goals, and practical considerations. Patients seeking maximum glucose control and significant weight loss should consider tirzepatide or semaglutide, despite higher costs. Those with established cardiovascular disease benefit from agents with proven cardiovascular protection: semaglutide, dulaglutide, or liraglutide.
Cost-conscious patients may prefer exenatide ER or lixisenatide, particularly if insurance coverage is limited. Patients prioritizing convenience should opt for weekly formulations, while those requiring precise dose adjustments may benefit from daily liraglutide. Elderly patients or those with dexterity issues often prefer dulaglutide's auto-injector design.
Clinical factors also influence selection. Patients with gastroparesis should avoid GLP-1 agents due to delayed gastric emptying effects. Those with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 can't use any GLP-1 medication. Kidney function impacts dosing for some agents, requiring careful monitoring.
We recommend consulting with a qualified physician to determine the most appropriate GLP-1 medication for your specific situation. FormBlends offers thorough physician assessments to evaluate your candidacy for GLP-1 therapy and develop personalized treatment plans based on your clinical profile and treatment goals.
Combining different GLP-1 receptor agonists isn't recommended due to overlapping mechanisms and increased risk of adverse effects without additional benefit. But GLP-1 medications can be safely combined with other diabetes drug classes including metformin, SGLT-2 inhibitors, and basal insulin.
Popular evidence-based combinations include GLP-1 agents with metformin for newly diagnosed patients, or GLP-1 plus SGLT-2 inhibitors for patients requiring both glucose control and cardiovascular protection. When combining with insulin, careful monitoring prevents hypoglycemia, and insulin doses often require reduction as GLP-1 effects develop.
Some patients benefit from combining GLP-1 therapy with other therapeutic peptides for thorough metabolic improvement, though such combinations require careful medical supervision and monitoring for potential interactions or adverse effects.
Liraglutide typically shows glucose-lowering effects within days due to daily dosing, while weekly agents like semaglutide and tirzepatide may take 2-4 weeks to reach steady-state effects. But all GLP-1 medications require 8-12 weeks to assess full therapeutic response.
GLP-1 medications are generally safe for elderly patients, with dulaglutide and liraglutide having the most extensive safety data in this population. Dose adjustments may be necessary for patients with kidney impairment, and careful monitoring is recommended during initiation.
Yes, patients can switch between GLP-1 medications under medical supervision. Switching typically involves stopping the current medication and starting the new agent at its recommended initial dose, with gradual titration as needed for optimal glucose control.
All GLP-1 medications require refrigeration (36-46°F) until first use. Once in use, most pens can be stored at room temperature for 28-56 days depending on the specific medication. Never freeze or expose to extreme temperatures.
Lixisenatide and dulaglutide generally have the lowest rates of gastrointestinal side effects, while tirzepatide has higher rates during dose escalation. All GLP-1 medications share similar side effect profiles, with nausea being the most common initial adverse effect.
GLP-1 medications are typically long-term treatments for type 2 diabetes. Clinical studies show sustained benefits over 3-5 years of continuous use, with many patients remaining on therapy indefinitely as part of thorough diabetes management.
Ready to explore GLP-1 therapy for your type 2 diabetes? Our physician-supervised approach ensures you receive the most appropriate medication based on your individual clinical profile and treatment goals. Take our free assessment to determine if GLP-1 therapy is right for you and receive personalized treatment recommendations from our experienced medical team.
Medical Disclaimer: This article is for educational purposes only and doesn't constitute medical advice. Individual responses to GLP-1 medications vary, and treatment decisions should always be made in consultation with a qualified healthcare provider. FormBlends physicians can help determine the most appropriate therapy based on your specific medical history, current medications, and treatment goals. Always consult your doctor before starting, stopping, or changing any diabetes medication.
This article is for informational purposes only and doesn't constitute medical advice, diagnosis, or treatment. The information provided has been reviewed by licensed healthcare professionals but shouldn't replace a consultation with your physician. Individual results vary. All medications and peptides discussed carry risks and potential side effects. Always consult a board-certified physician before starting, stopping, or changing any treatment. FormBlends provides physician-supervised telehealth services. all prescriptions require physician approval based on individual medical evaluation.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →Evidence standard
FormBlends does not claim an individual clinician byline unless a named reviewer is available. For this page, the editorial team checks medical and regulatory claims against primary sources, clinical trials, public datasets, and regulator guidance.
PubMed evidence trail
For Best GLP-1 for Type 2 Diabetes: All Agents Compared, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight
Supports head-to-head context when pages compare older and newer GLP-1 options.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Tirzepatide for Obesity Treatment and Diabetes Prevention
Supports newer discussion of obesity treatment and diabetes-prevention outcomes.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition
Supports body-composition, lean-mass, and metabolic-risk context.
PubMed
Comparison decision path
Direct answer
Best GLP-1 for Type 2 Diabetes: All Agents Compared should help you decide which option deserves a clinical review, not force a one-size answer.
Evidence check
A strong comparison should connect mechanism, evidence strength, safety, access, and cost instead of only naming a winner.
Safety check
The right choice can change based on history, medication interactions, side effects, budget, and availability.
Next step
After comparing, use the get-started flow to route your goals and health history into the right prescription review path.
Compare all FDA-approved GLP-1 medications for diabetes. Expert rankings based on efficacy, safety, cost & real-world outcomes. Tirzepatide vs Ozempic vs more. Use "Best GLP-1 for Type 2 Diabetes: All Agents Compared" to make the conversation more specific before you choose a provider, product, or next step. The page leans into comparison and decision support and the details behind semaglutide, tirzepatide, cost and coverage, safety and pharmacy quality. Because this article has 13 major sections, scan the headings first and then use the FAQ or summary sections to pressure-test the answer. The safest takeaway is a better checklist for clinician review, not a do-it-yourself medical decision.
Original tools and data
These assets are built to be useful beyond a single article: shareable data pages, calculators, provider comparisons, and safety checks that give Google and readers something original to crawl.
Editorial refresh
For this peptide therapy page, the 2026 refresh focuses on semaglutide, tirzepatide, BPC-157, cash-pay pricing, safety signals, best so the article stays close to the question behind "Best GLP".
The useful details are the practical ones: what to verify, what changes risk or cost, and which details separate Best GLP from nearby GLP-1, peptide, hormone, or provider-comparison searches.
Readers can use the added context to bring sharper questions to a licensed provider before making a treatment, cost, or care decision.
Custom 2026 image for Best GLP, peptide therapy, and better treatment decision-making.
A printable 2-page reference covering popular peptides, dosing ranges, stacking protocols, and storage.
Free download. We'll also send helpful GLP-1 guides to your inbox. Unsubscribe anytime.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication or treatment. FormBlends articles are source-checked against medical and regulatory references, but they are not a substitute for a personal medical consultation.
Written by FormBlends Editorial Research
Prepared by FormBlends Editorial Research. Claims are checked against primary regulatory, trial, label, and public-health sources where available. Reviewed by FormBlends Medical Team for medical accuracy, sourcing, and patient-safety framing.
Ready to get started?
Provider-reviewed GLP-1 and peptide therapy, delivered to your door.
Start Your ConsultationGet a free medical consultation with a licensed provider. Compounded GLP-1 medications starting at $99/month with free shipping.
Discover the top 7 GLP-1 medications for prediabetes prevention. Evidence-based rankings, clinical data, costs, and physician guidance for diabetes prevention.
Peptide TherapyThe best peptides for diabetes ranked by real evidence: GLP-1 agonists, GIP, amylin analogs. Mechanism, dosing, head-to-head comparison, and honest limits.
Conditions & TreatmentsGLP-1 peptides offer superior diabetes control with A1C reductions of 1.5-2.0% plus significant weight loss. Learn dosing, side effects, and costs.
Peptide TherapyMots-c for diabetes prevention. A guide covering the research, dosing protocols, side effects, and practical guidance for MOTS-c therapy.
Conditions & TreatmentsLearn how type 2 diabetes peptides like GLP-1 agonists and other therapeutic peptides can improve blood sugar control and metabolic health in 2026.
Conditions & TreatmentsLearn how specific peptides like GLP-1 agonists and growth hormone peptides can help reverse insulin resistance through improved glucose metabolism and cellular repair.
Provider-informed calculators to support your weight loss journey.
Check your body mass index and see if you may qualify for GLP-1 therapy.
Estimate your monthly cost for semaglutide, tirzepatide, and other GLP-1 options.
Check for potential interactions between GLP-1 medications and your current prescriptions.
Build a personalized titration schedule for your GLP-1 medication.